Bridging dose of U‐100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice‐daily glargine users

Documenti analoghi

• Comparable glycemic outcomes with insulin glargine and insulin degludec during exercise in adolescents with type 1 diabetes using a standardized management protocol
  di: Ivana Rabbone, et al.
  Pubblicazione: (2025)
• The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
  di: Yiming Mu
  Pubblicazione: (2024)
• Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China
  di: Nan Dai, et al.
  Pubblicazione: (2024)
• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  di: Jochen Seufert, et al.
  Pubblicazione: (2024)
• Insulin glargine 300 U/ ml versus insulin degludec 100 U/ ml improves nocturnal glycaemic control and variability in type 1 diabetes under routine clinical practice: A glucodensities‐based post hoc analysis of the OneCare study
  di: Fernando Gomez‐Peralta, et al.
  Pubblicazione: (2024)